Coeptis Therapeutics (NASDAQ:COEP) CEO David Mehalick joined Steve Darling from Proactive to share news the company, whose mission is to develop innovative cell therapy platforms for cancer, has announced a research agreement with the University of Pittsburgh to advance pre-clinical development of SNAP-CAR T cells. Mehalick telling Proactive SNAP-CAR, which Coeptis licensed from the University of Pittsburgh, is being researched with technology that can be adapted to different cancer indications including ovarian cancer.
Coeptis Therapeutics agrees to sponsored Research Agreement with the University of Pittsburgh
